Please assess the completion status of the following clinical trial:

Trial Title: High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ∙Patients with histologically confirmed primary central nervous system lymphoma or secondary CNS lymphoma defined as either synchronous CNS involvement of sys- temic NHL or as a site of recurrence in a patient s with a history of systemic NHL~  * Patients who achieved remission after first line chemotherapy and/or WBRT, or who experience relapse of PCNSL/SCNLS.~ * Patients who have not previously received therapy with high high-dose chemotherapy and stem cell transplantatitransplantation.~ * The performance st atus of the patients should be 2 or less by ECOG performance scale.~ * Patients should not have major illness or organ failure incompatible with autologous stem cell transplantation.~* Patients must have adequate hepatic function (serum bilirubin less than 2.0mg/dl, AST and ALT less than three times the upper normal limit)~* Patients must have adequate renal function ( serum creatinin less than 2.0mg/dl)~* Patients must have adequate cardiac function (ejection fraction 45% on echo- cardiogram)~* Patients must have adequate bone marrow function (ANC 1,000/mm 3 and platelet count 75,000/mm 3 ∙ All patients are fully informed about the nature and purpose of this study and informed consent should be given before the start of treatment. All patients should fully understand the right or trial abandon without any disadvantage.~Exclusion Criteria:~* Concurrent history of neoplasm other than CNS lymphoma with life expectancy less than 3 months.~* History of clinically significant cardiac dysfunction (ex. CHF, symptomatic CAD, uncontrolled arrhythmia) or MI within 12 months.~* psychiatric disorders or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible~* significant infection or uncontrolled bleeding~* enrollment of other clinical trials within 4 weeks prior to treatment~* any preexisting medical condition of sufficient severity to prevent full compliance with study~* patient being not willing to or unable to obey study protocol.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): Patients with histologically confirmed primary central nervous system lymphoma or secondary CNS lymphoma defined as either synchronous CNS involvement of sys- temic NHL or as a site of recurrence in a patient s with a history of systemic NHL~* Patients who achieved remission after first line chemotherapy and/or WBRT, or who experience relapse of PCNSL/SCNLS.~* Patients who have not previously received therapy with high high-dose chemotherapy and stem cell transplantatitransplantation.~* The performance st atus of the patients should be 2 or less by ECOG performance scale.~* Patients should not have major illness or organ failure incompatible with autologous stem cell transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).